Hepatitis B Vaccine MarketSize, Share & Industry Analysis, 2026-2034By TypeBy Distribution ChannelBy Age GroupBy TechnologyBy Application

Hepatitis B vaccines are prophylactic biological products administered to prevent infection with the hepatitis B virus, delivered either as a single-antigen dose or combined with other pediatric antigens such as diphtheria, tetanus, pertussis and polio in a single injection. They are purchased primarily by national immunization programs, hospitals and clinics for routine infant and childhood schedules, and by travel clinics, occupational health providers and adult primary care practices for catch-up and at-risk vaccination. Buyers range from government health ministries negotiating large-volume tenders to private clinics purchasing smaller quantities for individual patients.

The global hepatitis b vaccine market stood at USD 7.85 billion in 2025. A forecast-period rate of 5.72% takes it to USD 12.95 billion by 2034, and the study reports every year in between, passing USD 5.8 billion in 2020, USD 7.35 billion in 2024, USD 8.3 billion in 2026 and USD 10.53 billion in 2030.

Composition changes more than the total does. Combination, at 7.64%, outgrows Others at 3.95%, and its share moves from 40% to 47%. Single Antigen stays the largest line throughout, at USD 4.08 billion in 2025 and USD 5.96 billion in 2034. Combination take share over the period; Single Antigen and Others give it up while still growing in absolute terms.

Cut by distribution channel, the largest line is Hospitals: 48% of 2025 revenue, worth USD 3.77 billion, and 43% at USD 5.57 billion by 2034. Government Suppliers grows faster at 6.91% against 4.43%, moving from 42% of revenue to 46.5% by 2034. Both this axis and the type one divide the same revenue, which is why they are alternative views, not components.

Geographically, 39% of 2025 revenue sits in Asia Pacific (USD 3.06 billion rising to USD 5.44 billion) ahead of North America at 24% and USD 1.88 billion. Middle East and Africa is smallest, at 8%. Asia Pacific and Middle East and Africa gain share across the period, so growth is not distributed evenly between regions.

Behind these figures sit five regions, three type lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is triangulated from published sources and category proxies, with no independently sourced count behind it, and the same applies to the segment, regional and country breakdowns drawn from it.

• Revenue grows from USD 7.85 billion in 2025 to USD 12.95 billion in 2034, a compound annual rate of 5.72%, having reached USD 7.35 billion in 2024 from USD 5.8 billion in 2020.
• The largest line by type is Single Antigen, worth USD 4.08 billion and 52% of revenue in 2025, rising to USD 5.96 billion and 46% by 2034.
• At 7.64%, Combination grows faster than any other type line, moving from USD 3.14 billion and 40% of revenue in 2025 to USD 6.09 billion and 47% in 2034.
• Scenario range for 2034 runs from USD 11.91 billion in the bear case to USD 14.25 billion in the bull case, against a base-case USD 12.95 billion, the spread a plan built on this forecast has to absorb.
• The largest region is Asia Pacific, generating USD 3.06 billion in 2025 (39% of the global total) and USD 5.44 billion by 2034, ahead of North America at 24%.
• China accounts for 45% of Asia Pacific in the base year, worth USD 1.38 billion in 2025 and reaching USD 2.45 billion by 2034, the worked country example carried through that region's chapters.
• Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region, not as a single blended series.

Three things move over 2026-2034, and they are worth separating: the type mix, the regional balance, and the 5.72% compounding underneath both.

None of them reverses the market's direction. Every line and every region grows in absolute terms across the period; the movement is in which of them captures the revenue added.

The type mix tilts toward Combination. 7.64% against 3.95%: that gap, between Combination and Others, is the largest on the type axis. Over the forecast period that moves Combination from 40% of revenue to 47%, and Others from 8% to 6.9%. Neither contracts: USD 3.14 billion becomes USD 6.09 billion, USD 0.63 billion becomes USD 0.9 billion. What the spread decides is which of them a supplier's revenue is exposed to.

Growth concentrates in Asia Pacific and Middle East and Africa. Asia Pacific moves from 39% of revenue in 2025 to 42% in 2034, worth USD 3.06 billion rising to USD 5.44 billion; Middle East and Africa moves from 8% of revenue in 2025 to 9% in 2034, worth USD 0.63 billion rising to USD 1.17 billion. Share moves off the others in turn: North America at 24% moving to 22%, Europe at 20% moving to 18%, Latin America at 9% moving to 9%, each still growing in revenue terms. The practical consequence is that regional weighting decides whether a participant matches the market rate or trails it, regardless of how its own revenue reads.

A continuation, not an inflection. Reading the series: USD 5.8 billion in 2020, USD 7.35 billion in 2024, USD 7.85 billion in 2025, USD 8.3 billion in 2026, USD 10.53 billion in 2030 and USD 12.95 billion in 2034. No year breaks the trajectory, and the 5.72% forecast rate compares with 6.23% recorded over 2020-2025, a continuation, not an inflection. That moves the planning question away from timing a turn and onto the type and regional mixes, where the actual movement is.

Combination carries the market's growth rate

Separate the 5.72% into its parts and three show up: an already-large base compounding, the type mix moving toward its faster lines, and regional growth landing unevenly.

The bear case and what drives it

Where the forecast could be beaten

The total depends on a single line

USD 1.88 billion of 2025 revenue is generated in North America, 24% of the global hepatitis b vaccine market and reaches USD 2.85 billion by 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.

Share settles at 22% in 2034, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Single Antigen leads here as it does globally, at 52% of 2025 revenue, and Combination again grows fastest at 7.64%. Revenue for North America is broken out by every segmentation axis and by country in the full report.

The United States is the largest market within North America, generating USD 1.6 billion in 2025 and projected to reach USD 2.42 billion by 2034. 85% of the region in 2025 means the regional figures are, in practice, a view of this market with others attached. Set against USD 1.88 billion and USD 2.85 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

the United States buys along the same lines as the market globally; Single Antigen first at 52% of 2025 revenue and 46% in 2034, Combination fastest at 7.64% on a share moving from 40% to 47%. Because the country carries 85% of North America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Per-type revenue for the United States appears on its own in the full report.

Hepatitis B vaccines sold in the United States fall under the Food and Drug Administration's biologics framework, administered through its Center for Biologics Evaluation and Research. A manufacturer must secure a Biologics License Application before a product can enter interstate commerce, supported by evidence of safety, purity, and potency generated under Good Manufacturing Practice conditions. Lot release testing and ongoing pharmacovigilance through the national vaccine adverse event reporting system continue after approval. Labelling must carry the FDA-cleared prescribing information, including storage and handling instructions, and any change to the manufacturing process or formulation requires supplemental review. Inclusion on the recommended immunization schedule set by federal health advisory bodies also shapes uptake, since public and private purchasers generally align procurement with that schedule rather than acting independently of it.

The suppliers tracked in this study (GSK plc (U.K.), DYNAVAX TECHNOLOGIES CORPORATION (U.S.), VBI Vaccines Inc. (U.S.), Sanofi (France), Merck & Co., Inc. (U.S.), Beijing Minhai Biological Technology Co., Ltd. (China), Gilead Sciences, Inc. (U.S.), Beijing Tiantan Biological Products Co., Ltd. (China), Amy Vaccine Co., Ltd. (China), Shenzhen Kangtai Biological Products (China) and Others) compete in the United States across the type lines above. Two different problems sit on the same axis: holding Single Antigen at 52% of 2025 revenue, and taking Combination while it grows at 7.64%. The full report covers country-level positioning and shares company by company; this summary does not.

3.6% of global revenue is generated in Canada; USD 0.28 billion in 2025, reaching USD 0.43 billion in 2034, and 15% of North America.

In Europe, 20% of global revenue puts 2025 at USD 1.57 billion and reaches USD 2.33 billion by 2034. By revenue it sits third across the study, and the ranking does not change between 2025 and 2034.

18% of global revenue sits here in 2034, below the 2025 level, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

Within the region the type split tracks the global one; 52% of 2025 revenue in Single Antigen, fastest growth of 7.64% in Combination. Europe is reported axis by axis and country by country in the full study.

28% of Europe's base-year revenue comes from Germany; USD 0.44 billion, rising to USD 0.65 billion by 2034. At 28% of the region in 2025 it leads, but a majority of Europe's revenue is generated in other markets. Regional revenue of USD 1.57 billion in 2025 and USD 2.33 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Composition here matches the global split: the largest line is Single Antigen at 52% of 2025 revenue, easing to 46% by 2034, and the fastest is Combination at 7.64%, from 40% to 47%. With 28% of Europe concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Germany carries its own type breakdown in the full report.

As a European Union member state, Germany regulates hepatitis B vaccines through the centralised marketing authorisation procedure overseen by the European Medicines Agency, with the Paul-Ehrlich-Institut acting as the national competent authority for biomedicines and responsible for batch release testing before distribution. A manufacturer must demonstrate quality, safety, and efficacy in line with EU pharmaceutical legislation governing biological medicinal products, and manufacturing sites must hold current Good Manufacturing Practice certification. Labelling and the patient information leaflet must meet EU pharmaceutical labelling requirements, presented in German for the domestic market. Pharmacovigilance obligations continue after launch, with the Paul-Ehrlich-Institut and European authorities monitoring adverse events and coordinating any safety variations to the authorisation.

GSK plc (U.K.), DYNAVAX TECHNOLOGIES CORPORATION (U.S.), VBI Vaccines Inc. (U.S.), Sanofi (France), Merck & Co., Inc. (U.S.), Beijing Minhai Biological Technology Co., Ltd. (China), Gilead Sciences, Inc. (U.S.), Beijing Tiantan Biological Products Co., Ltd. (China), Amy Vaccine Co., Ltd. (China), Shenzhen Kangtai Biological Products (China) and Others are the suppliers covered in Germany. The commercially relevant division is 52% of 2025 revenue in Single Antigen, where the volume is, against 7.64% growth in Combination, where share moves. A supplier weighted toward Europe is competing over a base of USD 1.57 billion in 2025 reaching USD 2.33 billion by 2034, 20% of global revenue at the start of that period.

The United Kingdom is sized at USD 0.38 billion in 2025, rising to USD 0.56 billion by 2034; 4.8% of global revenue and 24% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

4% of global revenue is generated in France; USD 0.31 billion in 2025, reaching USD 0.47 billion in 2034, and 20% of Europe.

Asia Pacific holds 39% of the global hepatitis b vaccine market in 2025, worth USD 3.06 billion on the way to USD 5.44 billion by 2034. Among the five regions it ranks first by revenue in both years.

42% of global revenue sits here by 2034, up from the 2025 level, at a pace above the 5.72% global rate, so this region warrants separate treatment and should not be scaled off the total.

Within the region the type split tracks the global one; 52% of 2025 revenue in Single Antigen, fastest growth of 7.64% in Combination. The full report breaks Asia Pacific out along every axis and by country.

45% of Asia Pacific's base-year revenue comes from China; USD 1.38 billion, rising to USD 2.45 billion by 2034. Its 45% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. The region itself runs USD 3.06 billion to USD 5.44 billion over the same period, and this is the market carrying the country-level detail in the full report.

Composition here matches the global split: the largest line is Single Antigen at 52% of 2025 revenue, easing to 46% by 2034, and the fastest is Combination at 7.64%, from 40% to 47%. Its 45% weight in Asia Pacific means those movements carry straight into the regional totals. The full report reports China by type separately.

Hepatitis B vaccines in China are regulated by the National Medical Products Administration, which oversees registration through its Center for Drug Evaluation and reviews biological products under a dedicated vaccine administration framework. A manufacturer must obtain a drug registration certificate before marketing and hold a corresponding production licence, with each batch subject to mandatory lot release testing by an authorised institute before it can be sold. Facilities must comply with Good Manufacturing Practice standards specific to biological products, and packaging and inserts must meet national labelling requirements in Chinese. Given the vaccine's inclusion in the national immunization programme, additional coordination with public health procurement and adverse event monitoring systems applies alongside standard market authorisation.

Competition in China runs between the suppliers this study tracks: GSK plc (U.K.), DYNAVAX TECHNOLOGIES CORPORATION (U.S.), VBI Vaccines Inc. (U.S.), Sanofi (France), Merck & Co., Inc. (U.S.), Beijing Minhai Biological Technology Co., Ltd. (China), Gilead Sciences, Inc. (U.S.), Beijing Tiantan Biological Products Co., Ltd. (China), Amy Vaccine Co., Ltd. (China), Shenzhen Kangtai Biological Products (China) and Others. The commercially relevant division is 52% of 2025 revenue in Single Antigen, where the volume is, against 7.64% growth in Combination, where share moves. That makes Asia Pacific a 39% share of 2025 global revenue, USD 3.06 billion rising to USD 5.44 billion, for any supplier deciding where to concentrate.

Within Asia Pacific, India accounts for 25% of regional revenue and 9.8% of the global total, worth USD 0.77 billion in 2025 and USD 1.36 billion by 2034.

Within Asia Pacific, Japan accounts for 10% of regional revenue and 3.9% of the global total, worth USD 0.31 billion in 2025 and USD 0.54 billion by 2034.

USD 0.71 billion of 2025 revenue is generated in Latin America, 9% of the global hepatitis b vaccine market rising to USD 1.16 billion in 2034. It is a marginal region on this axis, fourth by revenue throughout the period.

9% of global revenue sits here in 2034, below the 2025 level, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

The type mix reported at global level applies here, with Single Antigen the largest line at 52% of 2025 revenue and Combination the fastest-growing at 7.64%. Per-axis and per-country detail for Latin America sits in the full report.

USD 0.32 billion of Latin America's 2025 revenue is generated in Brazil, the region's largest market, reaching USD 0.52 billion by 2034. 45% of the region in the base year makes it the largest market here without making it the region. Regional revenue of USD 0.71 billion in 2025 and USD 1.16 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in Brazil follows the type mix reported at global level: Single Antigen is the largest line at 52% of 2025 revenue, moving to 46% by 2034, while Combination grows fastest at 7.64% and takes its share from 40% to 47%. With 45% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Brazil carries its own type breakdown in the full report.

Brazil's national health surveillance agency, Anvisa, governs the registration and oversight of hepatitis B vaccines as biological products. A supplier must obtain product registration by submitting quality, safety, and clinical evidence, and manufacturing facilities are subject to Good Manufacturing Practice inspection under Anvisa's biological products framework before import or domestic distribution is permitted. Batch testing and release requirements apply to each production lot entering the market. Labelling must be in Portuguese and conform to Anvisa's packaging and information rules for injectable biologics. Because the vaccine is distributed widely through the public immunization programme run by the Ministry of Health, suppliers also coordinate with national procurement and pharmacovigilance reporting channels alongside their Anvisa obligations.

In Brazil the field is GSK plc (U.K.), DYNAVAX TECHNOLOGIES CORPORATION (U.S.), VBI Vaccines Inc. (U.S.), Sanofi (France), Merck & Co., Inc. (U.S.), Beijing Minhai Biological Technology Co., Ltd. (China), Gilead Sciences, Inc. (U.S.), Beijing Tiantan Biological Products Co., Ltd. (China), Amy Vaccine Co., Ltd. (China), Shenzhen Kangtai Biological Products (China) and Others. Two different problems sit on the same axis: holding Single Antigen at 52% of 2025 revenue, and taking Combination while it grows at 7.64%. A supplier weighted toward Latin America is competing over a base of USD 0.71 billion in 2025 reaching USD 1.16 billion by 2034, 9% of global revenue at the start of that period.

2.7% of global revenue is generated in Mexico; USD 0.21 billion in 2025, reaching USD 0.35 billion in 2034, and 30% of Latin America.

USD 0.63 billion of 2025 revenue is generated in Middle East and Africa, 8% of the global hepatitis b vaccine market on the way to USD 1.17 billion by 2034. By revenue it sits fifth across the study, and the ranking does not change between 2025 and 2034.

By 2034 the share has moved up to 9%, so the region grows faster than the market's 5.72% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

The type mix reported at global level applies here, with Single Antigen the largest line at 52% of 2025 revenue and Combination the fastest-growing at 7.64%. The full report breaks Middle East and Africa out along every axis and by country.

30% of Middle East and Africa's base-year revenue comes from Saudi Arabia; USD 0.19 billion, rising to USD 0.35 billion by 2034. At 30% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. The region itself runs USD 0.63 billion to USD 1.17 billion over the same period, and this is the market carrying the country-level detail in the full report.

Composition here matches the global split: the largest line is Single Antigen at 52% of 2025 revenue, easing to 46% by 2034, and the fastest is Combination at 7.64%, from 40% to 47%. Because the country carries 30% of Middle East and Africa, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Revenue by type for Saudi Arabia is reported separately in the full report.

The Saudi Food and Drug Authority regulates hepatitis B vaccines as biological products, requiring market authorisation before any supplier can register or distribute a vaccine within the Kingdom. Applicants must submit evidence of quality, safety, and efficacy, and manufacturing sites are expected to meet Good Manufacturing Practice standards recognised by the authority, whether through direct inspection or reliance on approvals from reference regulatory agencies. Imported products must carry Arabic-language labelling alongside the original packaging information, and each consignment is subject to release testing and customs clearance tied to SFDA registration status. Since the vaccine forms part of the Ministry of Health's national immunization schedule, coordination with public procurement and post-market surveillance obligations follows once registration is granted.

GSK plc (U.K.), DYNAVAX TECHNOLOGIES CORPORATION (U.S.), VBI Vaccines Inc. (U.S.), Sanofi (France), Merck & Co., Inc. (U.S.), Beijing Minhai Biological Technology Co., Ltd. (China), Gilead Sciences, Inc. (U.S.), Beijing Tiantan Biological Products Co., Ltd. (China), Amy Vaccine Co., Ltd. (China), Shenzhen Kangtai Biological Products (China) and Others are the suppliers covered in Saudi Arabia. Volume sits in Single Antigen at 52% of 2025 revenue; movement sits in Combination at 7.64% growth. The commercial size of that position is USD 0.63 billion in 2025 and USD 1.17 billion by 2034, 8% of the global total in the base year.

South Africa is sized at USD 0.16 billion in 2025, rising to USD 0.29 billion by 2034; 2% of global revenue and 25% of Middle East and Africa. It is reported separately from Saudi Arabia across every segmentation axis in the full report.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by type, distribution channel, age group, technology, application, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.